- OsteoSys is Korea's leading bone densitometer brand and the third-largest DXA equipment supplier worldwide
- TBS® is CE marked, FDA 510(k) cleared, and available in more than 60 countries
Geneva, Switzerland — November 14, 2022
Medimaps — the creator of TBS® (Trabecular Bone Score®), the global standard in bone microarchitecture assessment — today announced that TBS Osteo™ — a surrogate of bone microarchitecture boosted by AI — is now available on diagnostic platforms from OsteoSys Co., Ltd., the leading bone mineral densitometer brand in Korea and the third-largest supplier of DXA scanning equipment worldwide.
TBS Osteo™ is available on OsteoSys’s Primus Whole Body DXA, the company’s high-end DXA scanning product. The agreement expands worldwide access to Medimaps’ technology for clinicians across Southeast Asia, Europe, and South America. Financial terms were not disclosed.
Medimaps has obtained a CE 2797 mark for TBS Osteo™ and FDA 510(k) clearance in the US, and the software is cleared in more than 60 countries worldwide, including Japan and South Korea. TBS® is also reimbursable in the US and some European countries, and Medimaps is working toward reimbursement in Japan and Korea. TBS® is recommended for use by many local, national, and international medical societies, including in Switzerland, France, Italy, Germany, Spain, the United States, China, and Japan.
" Bone structure is just as important as bone mineral density (BMD) when diagnosing and treating osteoporosis. Along with BMD, TBS Osteo provides a more complete picture of patient fracture risk. We see TBS Osteo as a viable option integrated into our DXA scanners to address osteoporosis, a health concern that is growing rapidly as the worldwide population ages."
said Dr. Young-bok Ahn, CEO and founder of OsteoSys.
"Our proprietary and patented technology is empowered by a deep learning, multi-layer approach, which makes it applicable across a wide spectrum of image modalities and resolutions. TBS is demonstrating diagnostic accuracy improvement for primary and secondary osteoporosis, in both females and males, and appears sensitive to changes over time resulting from effective treatment (with TBS increasing) or continued bone loss in the absence of effective treatment (with TBS decreasing). Because it is seamlessly integrated into BMD assessment, TBS can be applied across a number of clinical settings, ranging from opportunistic X-ray-based screening to patient risk profiling and presurgical evaluation."
said Prof. Didier Hans, CEO and co-founder of Medimaps.
Osteoporosis is a condition of primary concern among aging patient populations. Patients at risk for osteoporotic fractures often receive a BMD assessment, which measures the quantity of bone but not its quality. TBS Osteo™ works alongside BMD and clinical risk factors to analyze bone microarchitecture as an assessment of bone quality. Within moments, the software provides practitioners with an easy-to-interpret score to quickly identify and classify patients’ fracture risk and implement a course of intervention. The technology uses the same images already acquired for BMD assessment, digital X-ray, or projected CT imaging, so patients are not exposed to additional radiation, and it integrates seamlessly into a physician’s clinical workflow to deliver a completed structured report.
About OsteoSys Co., Ltd.
Founded in 2000 and based in Seoul, South Korea, OsteoSys manufactures bone densitometer devices to treat and diagnose osteoporosis through a wide range of whole-body and peripheral DXA scanning offerings.